Luigi Marchionni, MD, PhD

Highlights

1
Vaccines · 2021
LMLuigi Marchionni
PMID: 33923159PMCID: PMC8145634DOISenior author47 citations
2
Molecular cancer research : MCR · 2024
BDBrian D. Robinson MLMassimo Loda LMLuigi Marchionni
PMID: 38284821PMCID: PMC10985477DOISenior author5 citations
3
Genome biology · 2023
LMLuigi Marchionni
PMID: 36759904PMCID: PMC9912678DOISenior author8 citations

176

6 grants

Co-I
Genomically-informed Morphological Stromal Signatures to Predict Lethal Prostate Cancer
U.S. Department of Defense · 2025–2028
HT9425-25-1-0385
Sub-PI
A cord-blood specific subset of human gamma-delta T cells with distinct functional features
National Institute of Allergy and Infectious Diseases · 2026–2028 · via University of Maryland
R21AI196697-01
Sub-PI
Radiation Oncology-Biology Integration Network on Oligometastasis (ROBIN OligoMET) Center (Shared Resources Core)
National Cancer Institute · 2022–2027 · via University of Maryland, Baltimore
U54CA273956-05
Co-I
Investigating cell-intrinsic and extrinsic interactions in prostate cancer at the single cell level ("Core A: Pathobiology")
National Cancer Institute · 2022–2027 · via Columbia University
P01CA265768-01
PI
Research Collaboration Agreement with Sanofi US Services, Inc
Sanofi S.A. · 2024–2026BioPharma Alliance
BP 250339-02
Sub-PI
Analysis of cord blood Vd2 T cell differentiation and function using CITE-seq and ATAC-seq
National Institute of Allergy and Infectious Diseases · 2024–2026 · via University of Maryland, Baltimore
R03AI182671-02

Completed grants (7)

PI
Collaborative Research: SCH: Integrated Analysis of Single-Cell and Spatially Resolved Omics Data
National Science Foundation · 2021–2025
NSF 213498-04
Co-I
Characterizing 3'-UTR biology as a mechanism of therapy response in high risk prostate cancer.
U.S. Department of Defense · 2024–2025
HT9425-24-1-0310
Co-I
Decoding Bone Metastasis in Prostate Cancer: A Multimodal Approach Integrating Genomics and Imaging Data
U.S. Department of Defense · 2024–2024
HT94252410381
PI
Pilot project for ROBIN collaborative
University of Maryland, Baltimore · 2024–2024
UMB 240371-01
Sub-PI
Phase 1/2 Study of Modern Immunotherapy in BCG-Relapsing Urothelial Carcinoma of the Bladder - (ADAPT-BLADDER)
National Cancer Institute · 2020–2024 · via The Johns Hopkins University
R01CA235681-05
Sub-PI
Bioinformatic-Chemical Approach to Credential Molecular Targets to Combat Rapid Chemo-Radiation Resistance in SCLC
National Cancer Institute · 2020–2023 · via The Johns Hopkins University
U01CA231776-05
PI
Hardwiring Mechanism into Predicting Cancer Phenotypes by Computational Learning
National Cancer Institute · 2021–2023
R01CA200859-06

2 studies

PI
Empowering Precision Medicine: Predicting Therapeutic Response in Ulcerative Colitis on Whole Slide Histopathology Images
Weill Medical College of Cornell University · OPEN TO ACCRUAL (as of 2025)
PI
A Research Data Repository for the Department of Pathology and Laboratory Medicine
Weill Medical College of Cornell University · OPEN TO ACCRUAL (as of 2020)

Researchers Customize AI Tools for Digital Pathology
July 9, 2024
Scientists from Weill Cornell Medicine and the Dana-Farber Cancer Institute in Boston have developed and tested new artificial intelligence (AI) tools tailored to digital pathology—a rapidly growing field that uses high-resolution digital images created from tissue samples to help diagnose disease and guide treatment.

Amazon Web Services, Inc. · CRISPR Therapeutics · Grail · Moderna, Inc. · NVIDIA Corporation

Dana-Farber Cancer Institute · The Johns Hopkins University